We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Oxford Biomedica plc (OXB) Ordinary 50p

Sell:337.00p Buy:339.50p 0 Change: No change
Market closed Prices as at close on 19 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:337.00p
Buy:339.50p
Change: No change
Market closed Prices as at close on 19 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:337.00p
Buy:339.50p
Change: No change
Market closed Prices as at close on 19 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

Contact details

Address:
Windrush Court, Transport Way
OXFORD
OX4 6LT
United Kingdom
Telephone:
+44 (01865) 783000
Website:
https://www.oxb.com/

Important dates

Future events
There are no future events available.
Past events
AGM 24 June 2024 24/06/24
Annual report 30 April 2024 30/04/24
Final results 29 April 2024 29/04/24
Interim results 20 September 2023 20/09/23

General stock information

EPIC:
OXB
ISIN:
GB00BDFBVT43
Market cap:
£355.93 million
Shares in issue:
105.30 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE techMARK 100,FTSE All Share,FTSE Small Cap,FTSE techMARK All Share

Key personnel

  • Frank Mathias
    Chief Executive Officer, Executive Director
  • Lucinda Crabtree
    Chief Financial Officer, Executive Director
  • Stuart Paynter
    Chief Financial Officer, Executive Director
  • Thierry Cournez
    Chief Operating Officer, UK Site Head
  • Lisa James
    Chief People Officer
  • James Miskin
    Chief Quality and Technical Officer
  • Matthew Treagus
    Chief Information Officer
  • Natalie Walter
    Group General Counsel, Company Secretary
  • Kyriacos Mitrophanous
    Chief Innovation Officer
  • Sebastien Ribault
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.